NDAORALTABLET
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
LOPID (gemfibrozil) by R-Pharm US is peroxisome proliferator-activated receptor alpha agonists [moa]. First approved in 1981.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOPID (gemfibrozil) is an oral small-molecule fibrate approved in 1981 that works as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist. It is primarily indicated for dyslipidemia and type 2 diabetes mellitus, with emerging research exploring utility in multiple sclerosis, Parkinson disease, anemia, pain, and cough. The drug reduces triglycerides and raises HDL cholesterol by activating nuclear receptors that regulate lipid metabolism.
$8KPart D
LOE ApproachingDeclining
With lifecycle approaching loss of exclusivity and minimal Part D spend, LOPID is a mature, low-volume brand with limited commercial expansion opportunity and a contracted team footprint.
Mechanism of Action
Peroxisome Proliferator-activated Receptor alpha Agonists
Pharmacologic Class:
Peroxisome Proliferator Receptor alpha Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention
Started Apr 2026
100 enrolled
Chronic Coronary Syndrome
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Started Nov 2025
96 enrolled
Drug Drug Interaction (DDI)
Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
Started Jul 2023
45 enrolled
CoughHealthy
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
Started Jul 2023
47 enrolled
Healthy Participants
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
Started Mar 2023
11,086 enrolled
Coronary Artery Disease
Worked on LOPID at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.